Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability.

TRON Group Inc. (OTC: TGRP), through its subsidiaries, is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, diabetes and infectious diseases. TRON Group Inc. subsidiaries include Nanopharmaceutics, Inc., a wholly-owned subsidiary, and Alchem Laboratories Corporation, a majority-owned subsidiary, both located in Alachua, Florida.